Neurotech bounces back from FDA rejection with new NTI164 baseline study
Neurotech (ASX:NTI) has bounced back from a recent fast-track status rejection from the FDA, now launching a NTI164 baseline data study.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.